Wang, Kun http://orcid.org/0009-0009-6503-4678
Hou, Liangzhen
Wang, Xin http://orcid.org/0000-0001-7440-1075
Zhai, Xiangwei http://orcid.org/0000-0003-2967-5573
Lu, Zhaolian
Zi, Zhike http://orcid.org/0000-0002-7601-915X
Zhai, Weiwei http://orcid.org/0000-0001-7938-0226
He, Xionglei http://orcid.org/0000-0003-1050-802X
Curtis, Christina http://orcid.org/0000-0003-0166-3802
Zhou, Da http://orcid.org/0000-0002-0272-6644
Hu, Zheng http://orcid.org/0000-0003-1552-0060
Article History
Received: 24 October 2022
Accepted: 28 June 2023
First Online: 31 July 2023
Competing interests
: C.C. is an advisor to and stockholder in Grail, Ravel and DeepCell and an advisor to Genentech, Bristol Myers Squibb, 3T Biosciences and NanoString. All other authors declare no competing interests.